Suppr超能文献

用于ChooseLD的数据驱动评分调整:一种基于结构的药物设计算法,具有经验评分和配体-蛋白质对接可预测性评估。

Data-driven score tuning for ChooseLD: A structure-based drug design algorithm with empirical scoring and evaluation of ligand-protein docking predictability.

作者信息

Masuda Akihiro, Sadato Daichi, Iwadate Mitsuo

机构信息

Department of Biological Sciences, Graduate School of Science and Engineering, Chuo University, Bunkyo-ku, Tokyo 112-8551, Japan.

Clinical Research and Trials Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo 113-0021, Japan.

出版信息

Biophys Physicobiol. 2024 Sep 21;21(3):e210021. doi: 10.2142/biophysico.bppb-v21.0021. eCollection 2024.

Abstract

Computerized molecular docking methodologies are pivotal in screening, a crucial facet of modern drug design. ChooseLD, a docking simulation software, combines structure- and ligand-based drug design methods with empirical scoring. Despite advancements in computerized molecular docking methodologies, there remains a gap in optimizing the predictive capabilities of docking simulation software. Accordingly, using the docking scores output by ChooseLD, we evaluated its performance in predicting the bioactivity of G-protein coupled receptor (GPCR) and kinase bioactivity, specifically focusing on Ki and IC values. We evaluated the accuracy of our algorithm through a comparative analysis using force-field-based predictions from AutoDock Vina. Our findings suggested that the modified ChooseLD could accurately predict the bioactivity, especially in scenarios with a substantial number of known ligands. These findings highlight the importance of selecting algorithms based on the characteristics of the prediction targets. Furthermore, addressing partial model fitting with database knowledge was demonstrated to be effective in overcoming this challenge. Overall, these findings contribute to the refinement and optimization of methodologies in computer-aided drug design, ultimately advancing the efficiency and reliability of screening processes.

摘要

计算机化分子对接方法在现代药物设计的关键环节筛选中起着核心作用。ChooseLD是一款对接模拟软件,它将基于结构和配体的药物设计方法与经验评分相结合。尽管计算机化分子对接方法取得了进展,但在优化对接模拟软件的预测能力方面仍存在差距。因此,我们使用ChooseLD输出的对接分数,评估了它在预测G蛋白偶联受体(GPCR)生物活性和激酶生物活性方面的性能,特别关注Ki和IC值。我们通过与基于力场的AutoDock Vina预测进行对比分析,评估了我们算法的准确性。我们的研究结果表明,改进后的ChooseLD能够准确预测生物活性,尤其是在已知配体数量众多的情况下。这些发现凸显了根据预测目标的特征选择算法的重要性。此外,利用数据库知识解决部分模型拟合问题被证明在克服这一挑战方面是有效的。总体而言,这些发现有助于完善和优化计算机辅助药物设计方法,最终提高筛选过程的效率和可靠性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c290/11718169/514bc5413f21/21_e210021-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验